for the establishment of an EBV serological status using of the VCA, EA and EBNA markers. 43
and LIAISON VCA IgM assays, the sensitivity was assessed with sera classified by the 147 reference assay as primary infections and early primary infections and the specificity with 148 sera classified as seronegative and past infections. For the VIDAS VCA/EA IgG and the 149 LIAISON VCA IgG + EA IgG assays, sensitivity was assessed with sera classified as primary 150 infections (excluding early primary infection) and as past infections. The specificity was 151 assessed with seronegative sera. For the VIDAS EBNA IgG and LIAISON EBNA IgG 152 assays, the sensitivity was assessed with sera classified as past infections (excluding isolated 153 VCA IgG profiles), and the specificity with sera classified as primary infections and with 154 seronegative sera. 155
The agreement between VIDAS profiles, LIAISON profiles and the expected EBV status was 156 established in accordance with the criteria of the respective manufacturers, through the 157 combined interpretation of the three VIDAS EBV markers or the four LIAISON EBV 158 markers. Of note, to establish these profiles, the LIAISON assay used different threshold 159 values for the VCA IgM test (20 and 40 U/mL) and for the EBNA IgG test (5 and 20 U/mL). 160
161

Statistical analysis 162
The sensitivity and specificity of each assay were determined in comparison to the EBV 163 reference assays. Equivocal results obtained with one of the assays were considered as 164 negative for sensitivity calculations and positive for specificity calculations. Table 4 . Overall, this 224 agreement was 89.7% with the VIDAS assay and 88.2% with the LIAISON assay. For both 225 assays, this agreement was better with EBV-seronegative sera and sera referenced as past 226 infection compared to specimens classified as primary infections. 227
The details of the differences between the expected EBV status with the EIA reference assays 228 and the profiles obtained with the LIAISON and VIDAS assays are shown in Tables 5 and 6 . 229
With the LIAISON assay applied to sera referenced as primary infection, the most frequently 230 reported discrepant profile was: "transition phase" (i.e., VCA IgG-, IgM, and EBNA-IgG 231 positive) (22/186; 11.8%) followed by the profile: "EBV seronegative" (5/186; 2.7%) ( Table  232 5). In sera referenced as past infection, the two most frequently reported discrepant profiles 233 were "isolated IgG VCA" (8/164; 4.9%) and "indeterminate" (8/164; 4.9%), always due to the 234 detection of isolated EBNA IgG. In the 157 sera referenced as EBV seronegative, the 235 LIAISON assay reported ten cases (6.4%) of "primary infection". 236
With the VIDAS assay (Table 6 ), 15 of the 186 samples (8.1%) referenced as primary 237 infections were reported as "indeterminate" and nine (4.8%) were reported as "EBV 238 seronegative". Among the 164 sera referenced as past infection, eight (4.8%) were reported as 239 11 sera referenced as EBV seronegative, the VIDAS assay reported four cases of "primary 241 infection" (2.5%) and three indeterminate profiles (1.9%). The second most common discrepant profile reported with both assays, performed with sera 290 classified as primary infection, was "EBV seronegative". Nine out of 186 (4.8%) referenced 291 as primary infections were reported as seronegative with the VIDAS assay as were five out of 292 186 (2.6%) with the LIAISON assay. This is, in part, due to the fact that nearly one-third of 293 the primary infections were sampled at the very beginning of the disease with only IgM 294 detectable with the reference EIA and defined as early primary infection. In about 25% of 295 these cases, both VIDAS and LIAISON assays detected neither VCA IgM nor VCA IgG. Of 296 note, some of these cases were retested during serological follow-up and most became 297 positive for VCA IgM and VCA IgG with both tests (data not shown). Both VIDAS and 298 LIAISON VCA IgG and VCA IgM tests use the VCA p18 antigen. Other EIA methods use 299 recombinant gp125 or P23 antigens for VCA antibody detection, which may increase 300 sensitivity during early primary infection (3, 4, 24). Thus, in the case of a strong clinical 301 suspicion of IM at the beginning of the disease, these results suggest that a serological follow-302 up could be helpful if the first serological result is entirely negative for EBV markers. 303
With sera reported as past infection with the reference assays, most of the discrepant EBV 304 profiles with the LIAISON assay were reported as "isolated VCA IgG" or "indeterminate 305 profile" with isolated EBNA IgG. In one case of past infection, the LIAISON interpretation 306 was "EBV seronegative". With the VIDAS assay, no past infection was misclassified as EBV 307 seronegative and the discrepant EBV profiles were reported as "isolated VCA IgG" or 308 "indeterminate profile". These indeterminate profiles corresponded to either the presence of 309 isolated EBNA IgG or the presence of the three VCA IgG, VCA IgM and EBNA markers. 310
Overall, in this study, "isolated VCA IgG" cases were detected in 1.7% and 2.5% of cases 311 with LIAISON and VIDAS, respectively, while "isolated EBNA IgG" cases were reported in 312 (19, 23, 32) , and indeterminate profiles with this EIA were reassessed with IFA in our 339 study. Nevertheless, since a definitive clinical diagnosis could not be obtained each time and 340 be retrospectively related to the serology results, we could not exclude some 341 misclassifications with the reference test. Another limitation of the study was that cross-342 reactive sera collected during acute infections such as CMV primary infection, hepatitis A, 343 hepatitis E and acute parvovirus B19 infections or sera collected during the course of 344 autoimmune diseases were not tested. These clinical situations could have an impact on the 345 specificity of the VCA IgM assay (3, 16). In addition, some of the sensitivity and specificity 346 values presented in this study could appear to be relatively low compared to other studies, 347 because we deliberately classified equivocal results as false-negative or false-positive results 348 in the statistical analysis. We also included a significant number of early primary infections, 349 which could not be the routine population for EBV testing. Finally, we did not perform a real 350 cost-effectiveness analysis for the two assays; we can only report that, in our hands, the 351 turnaround time of the two assays was similar (the EBV status was obtained after 35 and 40 352 min for the LIAISON and the VIDAS assays, respectively) and the LIAISON assay had a 353 higher throughput. 354
In conclusion, this study demonstrated the similar performance of the VIDAS and the 355 LIAISON assays for the convenient and clear differentiation of a primary EBV infection from 356 a past infection or absence of infection. This study also underlines that, since differences in 357 the sensitivity and specificity of each single EBV marker in a given commercial assay may be 358 observed, the concomitant use of at least three EBV markers is necessary to establish an 359 accurate EBV profile. These performance differences within a commercial assay have to be 360 known for a proper interpretation of the serology and could imply the use of more than one 361 automated assay to resolve certain difficult EBV profiles. 
